Most NCDs could be treated with small number of cheap generic drugs and within existing budgets

In the fifth Series paper, researchers led by Professor Hans Hogerzeil from the University of Groningen in the Netherlands say that most NCDs could be treated with a small range of inexpensive, off-patent medicines, and suggest that substantial improvements in availability of life-saving drugs in poorer nations could be achieved within existing budgets by more careful selection and sourcing of generic versions, and better targeting of people at highest risk.

They point to examples such as: generic insulin that could be made available in many low-income and middle-income countries at prices five to eight times cheaper that those currently paid for newer and branded products; and multidrug regimens for people at high- that could cost as little as US$1 per head per year and prevent 18 million deaths in 23 of the poorest nations over the next 10 years.

However, they say, better selection and procurement policies alone will not be enough to make life-saving medicines and vaccines affordable to all people that need them.

They outline several other key measures including: increased investment from domestic sources through tax-based or obligatory health-insurance; integrating drug management within existing initiatives for HIV/AIDS to achieve uninterrupted availability of NCD drugs and adherence to long-term treatment; increasing the unacceptable low availability of opioid medication for ; and coherent and equitable health and trade policies to guarantee access to newer, patented drugs.

"Access to medicines and vaccines to prevent and treat NCDs is unacceptably low worldwide. Only with these approaches [outlined in this paper] can a difference be made to the lives of hundreds of millions of current and future patients with NCDs", they conclude.

More information: www.thelancet.com/series/non-communicable-diseases

add to favorites email to friend print save as pdf

Related Stories

More AIDS patients may get cheaper drugs

Jul 12, 2011

(AP) -- Gilead Sciences Inc. will allow some of its AIDS drugs to be made by generic manufacturers, potentially increasing their availability in poor countries, particularly in Africa, officials said Tuesday.

Non-communicable diseases having devastating global impact

Aug 30, 2012

Non-communicable diseases (NCDs) such as heart disease, cancer and diabetes are no longer just a problem in wealthy nations – the rate of NCDs in low-to-middle income countries are increasing faster than in developed countries.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

17 hours ago

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.